Monthly Archives: November 2015

Biothera’s Imprime PGG and Monoclonal Antibody Therapy Alleviates Immune Suppression in Tumor Microenvironment and Increases Cancer Cell Killing

Company to Present New Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting NATIONAL HARBOR, MD — November 6, 2015 — New research provides additional scientific evidence that Biothera’s mid clinical stage cancer immunotherapy Imprime PGG acts as an immune ignition switch that enables the body to recognize and kill tumor cells. The company will present the data today at the Society for Immunotherapy...

Read More


Biothera’s Imprime PGG and Anti-Angiogenic Antibodies Work in Concert to Re-orient the Immune Microenvironment to Support Cancer Killing, Study Finds

BOSTON, November 6, 2015 — New preclinical research demonstrating the combination of Biothera’s Imprime PGG and anti-angiogenic antibodies re-orients the immune microenvironment to suppress tumor growth will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Imprime PGG is an immune potentiator that represents the next step in immune oncology. This mid clinical stage cancer immunotherapeutic is a first-in-class, well-tolerated,...

Read More


Biothera to Present Three Abstracts at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EAGAN, MN — November 2, 2015 — Biothera, a clinical stage biotechnology company pioneering the development of immune potentiators known as PAMPs for cancer immunotherapy, will present three abstracts at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5–9 at the Hynes Convention Center in Boston. PAMPs (Pathogen Associated Molecular Patterns) serve as critical recognition signals...

Read More